Protagen’s Cancer Immunotherapy Array will be used to identify autoantibody biomarkers that investigate the immunological profile and immuno-competence of long-term Glioblastoma survivors

Measuring serum autoantibodies in a liquid biopsy of prostate cancer patients, the team was able to successfully confirm tissue specific biomarkers via immunohistochemistry.